JP Morgan maintains Revvity at Neutral, raises price target to $160 from $155
JP Morgan kept its Neutral rating on Revvity but raised its price target to $160 from $155, citing a 3.2% increase. The new target suggests a 2.1% downside from the Nov 3 close of $163.48. Recent analyst notes on Revvity have price targets ranging from $172 to $185.
How this was made
The 30-second read
Why it matters
A new price target from a major bank can shift short‑term sentiment, but the stock already trades above the target, limiting upside.
Market read
Analyst target revision provides fresh data for traders; modest impact expected.
What to watch
Potential upcoming earnings or product announcements that could outweigh the modest target change.
Background
Revvity (RVTY) is a provider of life‑science instrumentation and consumables. Analyst coverage influences its valuation.
Ticker impact
JP Morgan raised its Revvity price target to $160 from $155, a new analyst action.
likely pressure as the market prices in the lower upside from the new target
Analyst target upgrades are fresh information; however, the stock trades above the new target, so investors may trim positions.
Market effects
Minor impact on the life‑sciences equipment sector as analysts adjust expectations for Revvity.
Limited to US markets where Revvity trades.
Low; the news is company‑specific.
Counterpoint
The price target increase may be overly optimistic given recent price weakness; investors could view it as a sell signal.
Key entities
- Financial InstitutionJP Morgan
Equity research analyst raising Revvity price target.
- CompanyRevvity
Life‑science equipment maker (ticker RVTY).
